Frontlight ResearchEarly access
TerminatedNo phase
Relationship Between Gut Microbiome, Probiotics, and Mild Cognitive Impairment
Key facts
- Who runs it
- Mackay Memorial Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 10 people enrolled
- Started
- 1 Apr 2022
- Ended
- 16 Jan 2024
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- PS23 live
- PS23 heat-treated
- Placebo
- Record updated
- 8 August 2025
- Why it stopped
- Difficult to include the patient.
Who can take part
- Age
- 40 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Patients who is suffering from Mild Cognitive Impairment
- Clinical Dementia Rating (CDR) 0.5
- Age 40-80 and willing to sign the Informed Consent
- Education level is above the junior high school level
- Healthy control who is eligible judged by PI
Who cannot take part
- Have undergone surgery of liver, bladder, or gastrointestinal tract
- Have current or history of inflammatory bowel disease
- Have history of cancer
- Known allergy to probiotics
- Dementia (MMSE ≤ 23)
- Cognitive Impairment caused by head injury
- History of cerebral apocalypse
- Other possible diseases may cause cognitive impairment, such as: Parkinson's disease, cervical mass, hydrocephalus or epilepsy
- Undergoing medication treatment for acute illness, Organic psychosis or diagnosed as psychiatric illness within 3 months or poor control of chronic psychiatric illness
- Patients on antibiotics within the preceding one month
- Patients using of other probiotic products (sachet, capsule or tablet) within the preceding two weeks
- Severely depressed patients (sick person health questionnaire-9 (PHQ-9) ≥ 20)
- Severe anxiety patients (Generalized Anxiety Dosorder 7-Item (GAD-7) ≧ 15)
- Undergoing parenteral nutrition
- Not eligible judged by PI
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is to evaluate whether the consumption of probiotics can improve the symptoms of patients with mild cognitive impairment; also evaluate the effects of probiotics on patients' blood, oxidation and stress related indicators.
The 4 groups in the trial
- PS23Treatment being tested
The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
Treatment: PS23 live
- heat-treated PS23Treatment being tested
PS23 heat-treated, 2 caps daily use.
Treatment: PS23 heat-treated
- placeboPlacebo, for comparison
The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
- Healthy ControlNo study treatment, for comparison
No intervention
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 8 August 2025